UNASSIGNED: OBJECT The prognosis of elderly @entity1 with @entity463 ( @entity463 ) is universally poor. Currently, few studies have examined postoperative outcomes and the effects of various modern therapies such as bevacizumab on survival in this @entity1 population. In this study, the authors evaluated the effects of various factors on overall survival in a cohort of elderly @entity1 with newly diagnosed @entity463 . METHODS A retrospective review was performed of elderly @entity1 (>=  65 years old) with newly diagnosed @entity463 treated between 2004 and 2010. Various characteristics were evaluated in univariate and multivariate stepwise models to examine their effects on complication risk and overall survival. RESULTS A total of 120 @entity1 were included in the study. The median age was 71 years, and sex was distributed evenly. @entity1 had a median Karnofsky Performance Scale (KPS) score of 80 and a median of 2 neurological symptoms on presentation. The majority (53.3%) of the @entity1 did not have any comorbidities. @entity5 most frequently (43.3%) involved the temporal lobe, followed by the parietal (35.8%), frontal (32.5%), and occipital (15.8%) regions. The majority (57.5%) of the @entity5 involved eloquent structures. The median @entity5 size was 4.3 cm. Every @entity1 underwent resection, and 63.3% underwent gross-total resection (GTR). The vast majority (97.3%) of the @entity1 received the postoperative standard of care consisting of radiotherapy with concurrent @entity2903 . The majority (59.3%) of @entity1 received additional agents, most commonly consisting of bevacizumab (38.9%). The median survival for all @entity1 was 12.0 months; 26.7% of @entity1 experienced long-term (>=  2-year) survival. The extent of resection was seen to significantly affect overall survival; @entity1 who underwent GTR had a median survival of 14.1 months, whereas those who underwent subtotal resection had a survival of 9.6 months (p = 0.038). Examination of chemotherapeutic effects revealed that the use of bevacizumab compared with no bevacizumab (20.1 vs 7.9 months, respectively; p < 0.0001) and @entity2600 compared with no @entity2600 (18.0 vs 9.7 months, respectively; p = 0.027) significantly improved survival. Multivariate stepwise analysis revealed that older age (hazard ratio [HR] 1.06 [95% CI1.02-1.10]; p = 0.0077), a higher KPS score (HR 0.97 [95% CI 0.95-0.99]; p = 0.0082), and the use of bevacizumab (HR 0.51 [95% CI 0.31-0.83]; p = 0.0067) to be significantly associated with survival. CONCLUSION This study has demonstrated that GTR confers a modest survival benefit on elderly @entity1 with @entity463 , suggesting that safe maximal resection is warranted. In addition, bevacizumab significantly increased the overall survival of these elderly @entity1 with @entity463 ; older age and preoperative KPS score also were significant prognostic factors. Although elderly @entity1 with @entity463 have a poor prognosis, they may experience enhanced survival after the administration of the standard of care and the use of additional chemotherapeutics such as bevacizumab.

XXXX in the elderly: the effect of aggressive and modern therapies on survival.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity2600 :: ('MESH:C051890', 'Chemical') :: ['irinotecan'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Tumors', 'tumors'] @entity2903 :: ('MESH:C047246', 'Chemical') :: ['temozolomide'] @entity463 :: ('MESH:D005909', 'Disease') :: ['GBM', 'glioblastoma']
@entity463 :: (MESH:D005909,Disease) :: ['Glioblastoma']
